Baltimore, Maryland 21215


Purpose:

The purpose of this research study is to understand if platelets in the blood become more active during cancer and specially advanced stages of cancer, in the future the investigators want to see if reducing platelet activity can improve survival in advanced cancer.


Study summary:

Hypotheses for proposed study Platelet reactivity as measured by percentage aggregation in response to agonists such as ADP is increased in patients with metastatic cancer compared to age sex and ethnicity matched controls. Platelet activation as measured by release of cytokines and vasoactive substances such as VEGF, TGF-beta, and PDGF is increased in patients with metastatic cancer compared to age sex and ethnicity matched controls. Study Design: Single center matched case control design; matching variables are age, sex and ethnicity Inclusion Criteria Cases: 25 adult patients (>18 years old) with any form of metastatic or advanced stage (TNM stage III or equivalent) solid adenocarcinoma including breast, colon, and lung cancer will be eligible for inclusion in this study with no restrictions related to previous chemotherapy, radiotherapy, biological therapy or surgical management at the time of enrollment or in the past., although we will prefer to recruit them prior to initiating chemotherapy. Controls: 25 patients will be selected based on age (+/- 5 years), sex and ethnicity matches from the outpatient medicine Clinic at Sinai hospital, as well as the Sinai community care clinic. Exclusion Criteria: Thrombocytopenia, defined as a platelet count of <100,000 at the time of recruitment of in the last available laboratory data History of known bleeding disorder or known platelet dysfunction Patients on antiplatelet treatment or anticoagulant therapies at the time of enrollment or 10 days prior to testing CKD stage IV or greater


Criteria:

Inclusion Criteria: Cases: 25 adult patients (>18 years old) with any form of metastatic or advanced stage (TNM stage III or equivalent) solid adenocarcinoma including breast, colon, and lung cancer will be eligible for inclusion in this study with no restrictions related to previous chemotherapy, radiotherapy, biological therapy or surgical management at the time of enrollment or in the past., although we will prefer to recruit them prior to initiating chemotherapy. Controls: 25 patients will be selected based on age (+/- 5 years), sex and ethnicity matches from the outpatient medicine Clinic at Sinai hospital, as well as the Sinai community care clinic. Exclusion Criteria: - Thrombocytopenia, defined as a platelet count of <100,000 at the time of - recruitment of in the last available laboratory data - History of known bleeding disorder or known platelet dysfunction - Patients on antiplatelet treatment or anticoagulant therapies at the time of enrollment or 10 days prior to testing - CKD stage IV or greater


NCT ID:

NCT02450175


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21215
United States

Judy Bosley, BSN, RN
Phone: 410-601-6120
Email: jbosley@lifebridgehealth.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.